A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Schwarz, Tino F.; Huang, Li‐Min; Valencia, Alejandra; Panzer, Falko; Chiu, Cheng-Hsun; Decreux, Annabelle; Poncelet, Sylviane; Karkada, Naveen; Folschweiller, Nicolas; Lin, Lan; Dubin, Gary; Struyf, Frank

doi:10.1080/21645515.2019.1625644

Cited by 39 publications

(39 citation statements)

References 44 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular clamp-stabilized S protein will be combined with GSK adjuvants. COVID-19 XWG-03 is a preclinical vaccine candidate developed by Xiamen University (Xiamen, China) and Xiamen Innovax Biotech using the GSK adjuvant AS04 (monophosphoryl lipid A and aluminum hydroxide) ( 97 ). COVID-19 XWG-03 is based on a series of truncated S proteins, which will be screened in combination with AS04.…”

Section: Vaccine Platform Technologiesmentioning

confidence: 99%

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

et al. 2020

View full text Add to dashboard Cite

There is an urgent need for effective countermeasures against the current emergence and accelerating expansion of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Induction of herd immunity by mass vaccination has been a very successful strategy for preventing the spread of many infectious diseases, hence protecting the most vulnerable population groups unable to develop immunity, for example individuals with immunodeficiencies or a weakened immune system due to underlying medical or debilitating conditions. Therefore, vaccination represents one of the most promising counter-pandemic measures to COVID-19. However, to date, no licensed vaccine exists, neither for SARS-CoV-2 nor for the closely related SARS-CoV or Middle East respiratory syndrome-CoV. In addition, a few vaccine candidates have only recently entered human clinical trials, which hampers the progress in tackling COVID-19 infection. Here, we discuss potential prophylactic interventions for SARS-CoV-2 with a focus on the challenges existing for vaccine development, and we review pre-clinical progress and ongoing human clinical trials of COVID-19 vaccine candidates. Although COVID-19 vaccine development is currently accelerated via so-called fast-track programs, vaccines may not be timely available to have an impact on the first wave of the ongoing COVID-19 pandemic. Nevertheless, COVID-19 vaccines will be essential in the future for reducing morbidity and mortality and inducing herd immunity, if SARS-CoV-2 becomes established in the population like for example influenza virus.

show abstract

Section: Vaccine Platform Technologiesmentioning

confidence: 99%

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cervarix induces high anti-HPV16 and 18 antibody titers and can prevent the incidence of infection for at least 10 years [ 36 , 37 ]. In addition, Cervarix invokes a significantly high and long-term cross-reactive immunogenicity against HPV31 and 45.…”

Section: Hpv Vaccine Efficacymentioning

confidence: 99%

“…In addition, Cervarix invokes a significantly high and long-term cross-reactive immunogenicity against HPV31 and 45. During a 10-year-follow-up study, over 85% of participants remained seropositive for anti-HPV31 and 45 antibodies following three doses of Cervarix [ 37 ]. In addition, Cervarix efficiently (>90%, injection prior to HPV exposure) protects against vaccine-targeted HPV related abnormalities and precancerous lesions, including cervical intraepithelial neoplasia 2 (CIN2), CIN3 and adenocarcinoma in situ (AIS) [ 38 , 39 ].…”

Section: Hpv Vaccine Efficacymentioning

confidence: 99%

Human Papillomavirus Vaccines: An Updated Review

2020

View full text Add to dashboard Cite

Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated information about current HPV vaccines, focusing on vaccine coverage and efficacy. In addition, pan-gender vaccination and current clinical trials are also discussed. Currently, more efforts should be put into increasing the vaccine’s coverage, especially in low- and middle-income countries. Provision of education on HPV and vaccination is one of the most important methods to achieve this. Vaccines that target HPV types not included in current vaccines are the next stage in vaccine development. In the future, all HPV-related cancers, such as head and neck cancer, and anal cancer, should be tracked and evaluated, especially in countries that have introduced pan-gender vaccination programs. Therapeutic vaccines, in combination with other cancer treatments, should continue to be investigated.

show abstract

“…80 An additional paper finds evidence for cross-protection, but no evidence for type replacement 11 y after the introduction of HPV vaccine in the U.S. 81 A study involving a 10-y follow-up of 10-14-y-old girls vaccinated with the bivalent vaccine found strong sustained antibody levels, with no severe adverse events attributable to the vaccine. 82 Another report looked at the effect of long intervals between doses of HPV vaccine on immune response, finding that intervals of several years do not negatively impact the immune response to the second dose. 83 Also in this section, there is an article involving evaluation of the feasibility of using a combined approach to HPV vaccination and screening (also known as FASTER) in Mexico.…”

Section: Oropharyngeal Hpvmentioning

confidence: 99%